AVEO
AVEO Pharmaceuticals, Inc.NASDAQ
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Mon, Nov. 28, 9:24 AM
    • AVEO Oncology's (NASDAQ:AVEO) European licensee of tivozanib EUSA Pharma has submitted its responses to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) Day 120 List of Questions, part of the centralized review process for a marketing authorization application (MAA). EUSA is seeking approval for the use of tivozanib for the first-line treatment of advanced renal cell carcinoma (RCC).
    • The next step in the filing process is the EMA Day 180 List of Outstanding Issues, expected in Q1.
    • Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is designed to optimize VEGF blockade while minimizing toxic side effects.
    • Previously: AVEO inks license deal for tivozanib in Europe for kidney cancer; shares up 31% (Dec. 21, 2015)
    | Mon, Nov. 28, 9:24 AM | 1 Comment
  • Fri, Nov. 4, 7:19 AM
    • AVEO Pharmaceuticals (NASDAQ:AVEO): Q3 EPS of -$0.07 beats by $0.05.
    • Revenue of $0.99M (-93.5% Y/Y) beats by $0.89M.
    | Fri, Nov. 4, 7:19 AM | 3 Comments
  • Mon, Aug. 15, 10:24 AM
    • AVEO Oncology (AVEO +1.5%) commences a Phase 1/2 clinical trial assessing the combination of lead product candidate tivozanib and Bristol-Myers Squibb's (BMY -0.1%) Opdivo (nivolumab) in patients with advanced renal cell carcinoma.
    • The Phase 1 portion will evaluate escalating doses of tivozanib in combination with nivolumab while the Phase 2 will assess the optimal dose of tivozanib combined with nivolumab.
    • Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is designed to optimize VEGF blockade while minimizing toxic side effects.
    | Mon, Aug. 15, 10:24 AM | 7 Comments
  • Thu, Aug. 4, 7:28 AM
    • AVEO Pharmaceuticals (NASDAQ:AVEO): Q2 EPS of -$0.13 beats by $0.01.
    • Revenue of $0.2M (+53.8% Y/Y) beats by $0.1M.
    • Press Release
    | Thu, Aug. 4, 7:28 AM
  • Thu, May 26, 7:31 AM
    • The first patient has been dosed in AVEO Oncology's (NASDAQ:AVEO) Phase 3 clinical trial, called TIVO-3, assessing lead product candidate tivozanib compared to sorafenib [Bayer's (OTCPK:BAYRY) Nexavar] in patients with refractory advanced renal cell carcinoma (RCC) who have failed at least two prior regimens including vascular endothelial growth factor tyrosine kinase inhibitor (VEGFR-TKI) therapy (other than sorafenib).
    • The 322-subject trial will randomize participants 1:1 to receive either tivozanib or sorafenib with no crossover between arms. The primary endpoint is progression-free survival at month 24. Top-line data are expected in Q1 2018.
    • Tivozanib¬†is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is designed to optimize VEGF blockade while minimizing toxic side effects. Sorafenib is a kinase inhibitor.
    | Thu, May 26, 7:31 AM
  • Fri, May 13, 9:15 AM
    • AVEO Oncology (NASDAQ:AVEO) inks a private placement of 17,642,482 units at $0.95 per unit to institutional investors yielding gross proceeds of ~$17M. Each unit consists of one share of common stock and one five-year warrant to purchase one share of common at $1.00. Closing date is May 18.
    • Net proceeds will fund the U.S. Phase 3 study of lead product candidate tivozanib, a combination trial of tivozanib and a PD-1 inhibitor and general corporate purposes.
    • Yesterday's close was $0.84.
    • Update: The private placement closed on May 18. Concurrently, the company amended its 2010 loan and security agreement with Hercules Capital which enabled it to borrow an additional $5M. Another $5M tranche may be borrowed in H1 2017 if certain conditions are met.
    | Fri, May 13, 9:15 AM | 1 Comment
  • Tue, Mar. 15, 9:48 AM
    • AVEO Pharmaceuticals (AVEO -10.4%) Q4 results: Revenues: $3.6M (+999%); R&D Expense: $3.9M (-55.2%); SG&A: $5.8M (+87.1%); Operating Loss: ($6.1M) (+53.1%); Net Loss: ($6.6M) (+52.5%); Loss Per Share: ($0.11) (+59.3%).
    • FY2015 results: Revenues: $19M (+5.0%); R&D Expense: $12.9M (-66.2%); SG&A: $14.2M (-23.7%); Operating Loss: ($12.4M) (+75.4%); Net Loss: ($15M) (+71.5%); Loss Per Share: ($0.27) (+73.3%); Quick Assets: $34.1M (-34.8%).
    • No guidance given.
    | Tue, Mar. 15, 9:48 AM
  • Tue, Mar. 15, 7:35 AM
    • AVEO Pharmaceuticals (NASDAQ:AVEO): Q4 EPS of -$0.11
    • Revenue of $3.6M vs. $0.12M in 4Q14
    | Tue, Mar. 15, 7:35 AM | 1 Comment
  • Dec. 21, 2015, 12:45 PM
    | Dec. 21, 2015, 12:45 PM | 3 Comments
  • Dec. 21, 2015, 10:29 AM
    • Nano cap AVEO Pharmaceuticals (AVEO +31.1%) enters into an exclusive license agreement with EUSA Pharma for the European rights to lead product candidate tivozanib for the treatment of advanced renal cell carcinoma (RCC). The deal also includes South Africa and additional countries in South America as well as additional potential indications.
    • Under the terms of the agreement, AVEO will receive an upfront payment of $2.5M, up to $394M in milestones and tiered royalties ranging from low double-digit to mid-20%. A portion of the milestones and royalties will be payable to Kyowa Hakko Kirin under a sublicensing deal.
    • EUSA plans to submit a Marketing Authorization Application (MAA) for tivozanib for the first-line treatment of advanced RCC in Q1.
    • Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). It is designed to optimize VEGF blockade while minimizing toxic side effects.
    | Dec. 21, 2015, 10:29 AM
  • Dec. 21, 2015, 9:18 AM
    | Dec. 21, 2015, 9:18 AM | 1 Comment
  • Nov. 9, 2015, 9:14 AM
    | Nov. 9, 2015, 9:14 AM
  • Nov. 9, 2015, 6:43 AM
    • AVEO Pharmaceuticals (NASDAQ:AVEO): Q3 EPS of $0.14 beats by $0.23.
    • Revenue of $15.16M (+1642.5% Y/Y) beats by $14.96M.
    | Nov. 9, 2015, 6:43 AM | 2 Comments
  • Aug. 24, 2015, 9:19 AM
    | Aug. 24, 2015, 9:19 AM | 14 Comments
  • Aug. 17, 2015, 12:44 PM
    | Aug. 17, 2015, 12:44 PM
  • Aug. 17, 2015, 9:15 AM
    | Aug. 17, 2015, 9:15 AM | 7 Comments